No abstract available
Keywords:
CYP3A; PPARA; UGT1A1; atazanavir; hyperbilirubinemia.
Publication types
-
Letter
-
Observational Study
MeSH terms
-
Adult
-
Atazanavir Sulfate / adverse effects*
-
Atazanavir Sulfate / pharmacokinetics*
-
Atazanavir Sulfate / therapeutic use
-
Cytochrome P-450 CYP3A / genetics*
-
Female
-
Glucuronosyltransferase / genetics*
-
HIV Protease Inhibitors / adverse effects
-
HIV Protease Inhibitors / pharmacokinetics
-
HIV Protease Inhibitors / therapeutic use
-
Humans
-
Male
-
Middle Aged
-
PPAR alpha / genetics*
-
Pharmacogenomic Variants / genetics
-
Polymorphism, Single Nucleotide / genetics
Substances
-
HIV Protease Inhibitors
-
PPAR alpha
-
Atazanavir Sulfate
-
CYP3A5 protein, human
-
Cytochrome P-450 CYP3A
-
CYP3A4 protein, human
-
UGT1A1 enzyme
-
Glucuronosyltransferase